Kahn Brothers Group Lowered Seaboard (SEB) Position; Dynavax Technologies (DVAX) Has 0.83 Sentiment

June 20, 2017 - By Linda Rogers

Kahn Brothers Group Inc decreased Seaboard Corp (SEB) stake by 3.56% reported in 2016Q4 SEC filing. Kahn Brothers Group Inc sold 309 shares as Seaboard Corp (SEB)’s stock declined 1.07%. The Kahn Brothers Group Inc holds 8,370 shares with $33.08 million value, down from 8,679 last quarter. Seaboard Corp now has $4.77 billion valuation. The stock increased 0.52% or $21.2 during the last trading session, reaching $4125. About shares traded. Seaboard Corp (NYSEMKT:SEB) has risen 36.88% since June 20, 2016 and is uptrending. It has outperformed by 20.18% the S&P500.

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The company has market cap of $415.57 million. The Firm is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It currently has negative earnings. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Clovis Capital Management Lp holds 1.69% of its portfolio in Dynavax Technologies Corporation for 41,669 shares. New Leaf Venture Partners L.L.C. owns 256,381 shares or 0.73% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 0.37% invested in the company for 485,000 shares. The California-based Redmile Group Llc has invested 0.36% in the stock. Amici Capital Llc, a New York-based fund reported 100,000 shares.

Since January 1, 0001, it had 1 buy, and 0 selling transactions for $24,240 activity.

About 2,833 shares traded. Dynavax Technologies Corporation (DVAX) has declined 63.84% since June 20, 2016 and is downtrending. It has underperformed by 80.54% the S&P500.